BLUE vs. OTLK, BCAB, LIFE, VIGL, SGMO, ALVR, CRIS, PLX, CRDL, and ATRA
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Outlook Therapeutics (OTLK), BioAtla (BCAB), aTyr Pharma (LIFE), Vigil Neuroscience (VIGL), Sangamo Therapeutics (SGMO), AlloVir (ALVR), Curis (CRIS), Protalix BioTherapeutics (PLX), Cardiol Therapeutics (CRDL), and Atara Biotherapeutics (ATRA). These companies are all part of the "biological products, except diagnostic" industry.
Outlook Therapeutics (NASDAQ:OTLK) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 5.3% of Outlook Therapeutics shares are held by insiders. Comparatively, 2.1% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, bluebird bio had 7 more articles in the media than Outlook Therapeutics. MarketBeat recorded 14 mentions for bluebird bio and 7 mentions for Outlook Therapeutics. bluebird bio's average media sentiment score of 0.24 beat Outlook Therapeutics' score of 0.08 indicating that Outlook Therapeutics is being referred to more favorably in the media.
Outlook Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Outlook Therapeutics currently has a consensus target price of $46.43, suggesting a potential upside of 450.71%. bluebird bio has a consensus target price of $5.74, suggesting a potential upside of 522.50%. Given Outlook Therapeutics' higher possible upside, analysts plainly believe bluebird bio is more favorable than Outlook Therapeutics.
bluebird bio received 881 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 70.32% of users gave Outlook Therapeutics an outperform vote.
Outlook Therapeutics has a net margin of 0.00% compared to Outlook Therapeutics' net margin of -419.64%. Outlook Therapeutics' return on equity of -34.32% beat bluebird bio's return on equity.
Outlook Therapeutics has higher earnings, but lower revenue than bluebird bio. Outlook Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Summary
bluebird bio beats Outlook Therapeutics on 11 of the 17 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
